Biotech Investor Sentiment Worsens in April After Samchundang Pharm Controversy
Concerns Over Inflation and Rising Market Interest Rates Also Weigh on Sector

Despite the rebound in the Korean stock market since April, the stock prices of a significant number of biotech companies continue to decline. Getty Images

Despite the rebound in the Korean stock market since April, the stock prices of a significant number of biotech companies continue to decline. Getty Images

View original image


Samchundang Pharm, which once held the title of "KOSDAQ blue-chip" due to a sharp surge in its stock price, has seen investor sentiment toward biotech stocks freeze after a steep drop triggered by a series of controversies. Despite a rebound in the domestic stock market since April, the share prices of many biotech companies continue to decline. Large KOSDAQ exchange-traded funds (ETFs) with significant allocations to Samchundang Pharm are also struggling due to poor returns.


Samchundang Pharm Turns from 'Heaven' to 'Hell': Shares Halved in Two Weeks After Peaking at 1.15 Million Won, Bio Investor Sentiment Freezes View original image

Biotech Investor Sentiment Worsens in April After Samchundang Pharm Controversy

According to the Korea Exchange on April 14, Samchundang Pharm's share price closed at 526,000 won in the regular session the previous day. Having traded in the low 200,000-won range at the beginning of the year, Samchundang Pharm's stock soared to 1.15 million won on March 30 on expectations for the development of an oral insulin, briefly becoming the KOSDAQ's top company by market capitalization. However, the share price has plummeted by more than half in just two weeks.


The sharp decline in Samchundang Pharm's stock is attributed to multiple negative factors, including news of a block deal (large-scale stake sale) by the largest shareholder and patent-related controversies. In response to the steep drop, the company held a press conference to announce the withdrawal of the block deal and to clarify issues related to contracts and patents, but these efforts failed to stop the share price from falling.


As the stock price dropped, biotech ETFs that included Samchundang Pharm in their portfolios also underperformed. While the KOSPI index has risen by around 14% this month, the Kodex Healthcare ETF declined by 2.5%, and the Tiger Healthcare ETF dropped by 2.7%. The Tiger KOSDAQ 150 Biotechnology ETF, which had a high allocation to Samchundang Pharm, fell by 5.7% this month, while the Coact Biohealthcare Active ETF dropped by 5.4%.


It is analyzed that the controversies surrounding Samchundang Pharm have led to declines in the stock prices of other pharmaceutical and biotech companies as well, resulting in lower returns for biotech ETFs overall. Since biotech stocks account for about 30% of the KOSDAQ's market capitalization, the KOSDAQ index has only risen 4.5% compared to the previous month.


The sharp rise in international oil prices after the war between the United States and Iran has also contributed negatively to the stock market by fueling inflation concerns and pushing up market interest rates. Typically, rising interest rates dampen investor sentiment for high-growth stocks such as biotech companies. An industry insider pointed out, "While the KOSPI has rebounded significantly this month amid hopes for an end to the war, the weaker rebound in the KOSDAQ is largely due to the poor performance of biotech stocks."

Inseok Jeon, CEO of Samchundang Pharm, is speaking at a press conference held on the 6th at the Samchundang Pharm headquarters in Seocho-gu, Seoul. Photo by Yonhap News

Inseok Jeon, CEO of Samchundang Pharm, is speaking at a press conference held on the 6th at the Samchundang Pharm headquarters in Seocho-gu, Seoul. Photo by Yonhap News

View original image

Financial Supervisory Service Moves to Improve Biotech Disclosure Standards

With investment uncertainty surrounding biotech stocks growing, financial authorities have launched efforts to improve related disclosure systems. The Financial Supervisory Service (FSS) established a task force (TF) on April 12 to enhance the clarity and structure of disclosures by pharmaceutical and biotech companies, enabling investors to intuitively understand key information.


This initiative responds to ongoing criticism that complicated language in disclosures about clinical trials and technology transfers makes it difficult for investors to understand key information from biotech companies. Over the next three months, the task force plans to gather opinions from the market and experts and discuss comprehensive improvements to pharmaceutical and biotech disclosures.


An FSS official emphasized, "Despite the significant presence of pharmaceutical and biotech companies on the KOSDAQ, the disclosure information available to investors remains difficult to understand," adding, "The task force will focus on redesigning the structure and language of disclosures to be more investor-friendly."



This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing